Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15667923 | 1.00 | EPHX1 (1.00) | EPHX1HIF1AALDH1A1CYP1A2APLNR | |
| Dicyclohexylcarbodiimide SCHEMBL303 | 1.00 | EPHX1 (1.00) | EPHX1HIF1AALDH1A1CYP1A2APLNR | |
| SCHEMBL11842065 | 1.00 | EPHX1 (1.00) | EPHX1HIF1AALDH1A1CYP1A2APLNR | |
| SCHEMBL21986399 | 1.00 | EPHX1 (1.00) | EPHX1HIF1AALDH1A1CYP1A2APLNR | |
| Dicyclohexylcarbodiimide SCHEMBL28535893 | 0.97 | EPHX1 (0.94) | EPHX1HIF1AALDH1A1CYP1A2APLNR | |
| Dicyclohexylcarbodiimide SCHEMBL22804053 | 0.97 | EPHX1 (0.94) | EPHX1HIF1AALDH1A1CYP1A2APLNR | |
| Dicyclohexylcarbodiimide SCHEMBL6931632 | 0.97 | EPHX1 (0.94) | EPHX1HIF1AALDH1A1CYP1A2APLNR | |
| Dicyclohexylcarbodiimide SCHEMBL1073570 | 0.97 | EPHX1 (0.94) | EPHX1HIF1AALDH1A1CYP1A2APLNR | |
| Dicyclohexylcarbodiimide SCHEMBL28399447 | 0.97 | EPHX1 (0.94) | EPHX1HIF1AALDH1A1CYP1A2APLNR | |
| SCHEMBL1290378 | 0.97 | EPHX1 (0.93) | EPHX1HIF1AALDH1A1CYP1A2APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117659119-A | RGD fragment, method for preparing polypeptide by utilizing RGD fragment and application of RGD fragment | 珠海市藤栢医药有限公司 | 2024-03-08 | — | — | CN | disclosed |
| WO-2023214632-A1 | METHOD FOR MANUFACTURING MYCELIUM MAT INTO LEATHER BY USING PH-CONTROLLED TANNIC ACID | 주식회사 마이셀 | 2023-11-09 | — | — | WO | disclosed |
| CN-112125805-B | Water-soluble magnolol derivative, preparation method of honokiol derivative and intermediate thereof, and related monohydroxy protected intermediate | 北京红惠新医药科技有限公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-110015966-A | A kind of preparation method of meclofenoxate hydrochloride | 广东先强药业有限公司 | 2019-07-16 | — | — | CN | disclosed |
| CN-108929340-A | Proline boric acid compound and its preparation method and application | 北京大学 | 2018-12-04 | — | — | CN | disclosed |
| CN-108884044-A | PIPERIDINE DERIVATIVE | 大塚制药株式会社 | 2018-11-23 | — | — | CN | disclosed |
| CN-108794520-A | The synthetic method of boric acid citric acid ester type compound including Ai Shazuo meter | 北京大学 | 2018-11-13 | — | — | CN | disclosed |
| CN-108727582-A | Target anticancer conjugate | 博瑞生物医药（苏州）股份有限公司 | 2018-11-02 | — | — | CN | disclosed |
| CN-108727584-A | Anticancer conjugate | 博瑞生物医药（苏州）股份有限公司 | 2018-11-02 | — | — | CN | disclosed |
| CN-108727583-A | Multi-arm target anticancer conjugate | 博瑞生物医药（苏州）股份有限公司 | 2018-11-02 | — | — | CN | disclosed |
| WO-2003043625-A1 | 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE S.P.A. (IT) | 2003-05-30 | — | — | WO | disclosed |
| WO-2003029187-A1 | QUATERNARY AMMONIUM SALTS OF OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE S.P.A. (IT) | 2003-04-10 | — | — | WO | disclosed |
| CN-1100788-C | Peptide for vaccine of schistosomiasis | UNIV BEIJING (CN) | 2003-02-05 | — | — | CN | disclosed |
| US-20020183519-A1 | Antithrombotic carboxylic acid amides | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-12-05 | — | — | US | disclosed |
| US-20020115685-A1 | Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2002-08-22 | — | — | US | disclosed |
| CN-1299359-A | Benzofurylpyrone derivatives | TEIJIN LTD (JP) | 2001-06-13 | — | — | CN | disclosed |
| CN-1235164-A | Peptide for vaccine of schistosomiasis | UNIV BEIJING MEDICAL (CN) | 1999-11-17 | — | — | CN | disclosed |
| US-5262085-A | FOR USE IN LIQUID CRYSTAL AND ELECTROOPTICAL DISPLAY ELEMENTS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-11-16 | — | — | US | disclosed |
| US-5246622-A | LIQUID CRYSTAL RACEMIC MIXTURE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL ELEMENT, PROCESS FOR MANUFACTURING LIQUID CRYSTAL ELEMENT, AND USES OF LIQUID CRYSTAL ELEMENT | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1993-09-21 | — | — | US | disclosed |
| US-5095139-A | Fungicides | CIBA-GEIGY CORPORATION (US) | 1992-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115685-A1 | Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | CYP2C9, ADRM1, ADRA1D | EPHX1 1439/4885HIF1A 2609/4885ALDH1A1 503/4885 |
| US-20020183519-A1 | Antithrombotic carboxylic acid amides | SERPINC1, TFPI, F2 | EPHX1 439/4885HIF1A 284/4885ALDH1A1 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.